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Abstract. The applicability was investigated of automated spectrophotometric heparin
assays and three clotting assays for determination of two low molecular weight (LMW) hep-
arin fractions: Org 10172 and DxNl0 and two infractionated commercially available hepa-
rins. The relative activity of the two commercially available heparins was similar in the
anti-Xa assay, in the anti-Ila assay and in 3 clotting assays. The LMW heparins showed
markedly different relative activity in all 5 assays. The activities of those heparin preparations
relative to the standard heparin were compared in the 5 assays, but standardization against a
standard heparin preparation appeared impossible. Methods of heparin determination can be
used to monitor treatment with a heparin preparation only if the same preparation is used as a
reference substance.
Introduction
Heparin fractions separated on basis of
molecular weight or affinity to antithrombin
III (AIIII) show variations in their catalytic
activity on the inactivation of factor Xa and
of thrombin [-3]. Much research work is
being done on this subject. Crude heparin is
suspected to contain many inactive or even
harmful components and it is generally ex-
pected that heparin fragments can be isolated
that have a specific antithrombotic action
more pronounced than that of crude heparin.
Selected fractions of heparin of low molecu-
tar weight (LMW) are expected to be avail-
able for clinical use in the near future. Clini-
cians will then ask for monitoring tests or for
quantihcation of these heparins in patient
plasmas.
We therefore investigated the applicabil-
ity of automated spectrophotometric heparin
assays and three clotting assays for determi-
nation of several commeicial heparins and of
Org Fl0172 and DxNl0 in plasma. For each
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heparin preparation, we compared the rela-
tive activity in normal human pooled plasma
in 3 clotting assays and in 2 spectrophoto-
metric heparin assays, based on factor Xa
and on factor IIa inactivation.
Materials and Methods
Citrated Plasma. By means of a vacuum system
with a multisample needle, blood was draw from the
antecubital vein. The first tube was used for other pur-
poses. A second tube (Venoject, black stopper, 4.5 mi,
3.80/o tri-Na-citrate) was drawn for routine clotting
determinations. Within l5 min, the latter sample was
centr i fuged (10 min, 3,500 g l5'C). The plasma thus
obtained contained less than 3 X 10e platelets/I.
Pooled Plasma. Equal volumes of citrated plasma
from thirty healthy donors were mixed and stored at
-70'C in al iquots of I  ml.
Antithrombin III trom KabiVitrum, Amsterdam
contained 10 U per vial. One unit is defined as the
activity found in I ml normal plasma. The contents of
each vial were dissolved in l0 ml distilled water. A
small amount of standard heparin was added to titrate
heparin neutralisation [5].
Thrombin (Roche, Basel). The contents of each vial
(120 USP Units of Bovine Thrombin) were dissolved
in 2.4 ml distilled water. Before use I vol thrombin
was diluted with 5 vol buffer I.
Factor Xa used was bovine factor Xa from Kabi-
Vitrum, Amsterdam. The contents of each vial (con-
taining 7l nkat) were dissolved in l0ml distillec
water.
Heparins were obtained from Leo, Emmen, Hof
land (heparin Leo batch No. 8ll14l4 and heparin
standard 181021) and from Organon, Oss, Holland
(Thromboliquine batch No. 128386). According to the
manufacturers, the solutions contained 5,000 USp
U/ml of the sodium salt, dilutions were made with
buffered saline (147 mM NaCl, 6.52 mM Na2HPOa,
1.62 mM KHzPOa, pH 7.35).
Heparin fractions of low molecular weight (MW
5,000) were donated by KabiVitrum, Stockholm
(DxNl0, 170 anti-Xa Units/mg) and by Organon, Oss
(Org 10172 high affinity heparinoid, 100 mglml). Di-
lutions were made with buffered sr,line (147 m!,[
NaCl, 6.52 mM Na2HPOa,, 1.62 mM KH2POa, pH
7.35) .
APTT Reagenls. (l)'Kaolin/platelet substitute'
from Diagnostic Reagents Ltd., Thame, Oxon, En-
gland. (2)'Actin-activated cephaloplastin reagent'
from Dade, Salm en Kipp, Breukelen, Holland.
(3)'APTT Automated' from General Diagnostics,
Amsterdam, Holland.
Chromogenic substrates used were: Benz-Ile-Glu-
Gly-Arg-pNA.HCl and H-D-Phe-Pip-Arg-pNA.2HCl
(5-2222 and 5-2238 both from KabiVitrum, Amster-
dam). The substrates were dissolved in distilled wa-
ter.
Buffer I (pH 8.4 and I0.2) contained di-Na-EDTA
(7 .5 mM, Tris-HCl (50 mM and NaCl (1'l5 mIuI).
Clotting assays were performed as indicated by the
manufacturer of the reagent, on a 'KC10' coagulom-
eter (Salm en Kipp, Breukelen, The Netherlands).
Plasma was incubated with the APTT-reagent in plas-
tic tube. After recalcification, the clotting time was
measured.
Automated chromogenic heparin dssdys were per-
formed on a 'Corona batch analyser' (Clinicon Am-
sterdam) as reported before [4].
Results
A reference curye of pooled plasma spiked
with known amounts of a standard heparin
(in USP units/l) was made for each of the 2
spectrophotometric heparin assays and the 3
APTT assays. Response curves based on
units or milligrams (as indicated by the man-
ufacturers) were constructed with the other
preparations (fig. l-5).
The anti-Xa and anti-Ila activities of the
diflerent heparin dilutions were read from
the standard reference curve and divided by
the heparin concentration (U or mg) indi-
cated by the manufacturer and corrected for
the dilution. The obtained ratios (table I) ex-
press the activities of the different heparins
relative to the standard heparin in the assay
concerned.
The activity of Heparin Leo is in all assays
comparable to the activity of the standard,
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Fig. l. Reference curves ofthe spectrophotometric
heparin assay with 5-2238 and thrombin with 5 hepa-
rins. For curve o, 100 U correspond to 500 mg ofthe
heparinoid. o = Heparin Leo; a - thromboliquine; o =
heparin standard; 1 = heparin DxN 10; n = heparinoid,
Org. lol72.
Fig. 3. Reference curves of the ac-
tivated partial thromboplastin time
with 'Actin' with 5 heParins. For
curve o, 100 U correspond to 62.5 mg
of the heparinoid. All preparations
clotted at concentrations up to 800
U/1. See legend to figure I for symbol
explanations.
Fig. 2. Reference curves ofthe spectrophotometnc
heparin assay with 5-2222 and factor Xa with 5 hepa-
rins. For curve tr, 100 U correspond to 50 mg ofthe
heparinoid. See legend to figure I for symbol explana-
tions.
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Fig.S. Reference curves of the activated partial
thromboplastin time with'APTT automated' with 5
heparins. For curve o, I 00 U correspond to 62.5 mg of
the heparinoid. Only heparin standard and heparin
fragment DxNl0 would clot at concentrations of 600
U/1. None would clot at higher concentrations. See
legend to figure I for symbol explanations.
Fig.4. Reference curves of
the activated partial thrombo-
plastin time with'kaolin-cefalin'
with 5 heparins. For curve tr,
100 U correspond to 62.5 mg of
the heparinoid. Heparin Leo,
thromboliquine and heparin
standard did not form a clot at
concentrations above 600 U/1.
See legend to figure 1 for explai
nations of symbols.
also from Leo. The same holds for the hepa-
rin activity of thromboliquine, although the
relative activity appears higher than the ex-
pected 1.0 in the spectrophotometric assays.
The relative activities of the LMW hepa-
rins depend strongly on the assay and re-
agents used. The relative anti-Xa activity of
heparin fraction DxNl0 varies from l.l2 to
1.42 and the relative anti-thrombin activity
varies from 2.69 to 3.07. The least diflerence
in clotting activity is observed in the APTT
with actin, the relative activity in the kaolin-
cephalin APTT is smaller than 1.0.
The activity of the heparinoid Org 10172
is not given by the manufacturer. In our
experiments dilution was chosen to obtain
comparable response curves. consequently,
the relative activities are expressed in U/mg.
The relative anti-thrombin activity of hepa-
rinoid Org. 10112 is dependent on the dilu-
tion. The relative anti-Xa activity ranges
from 2.08 to 2.86. The relative activities in
the clotting assays are strongly dependent on
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Table I. Reiative heparin activities: heparin activities determined with the anti-Ila assay and with the anti-
Xa assay expressed as ratio to the activity of heparin standard
Dilution Heparin Leo Thromboliquine KabiVitrum DxNl0 Org. 10172,U/mg
AntiIIa assay
1 :20
2:20
3:20
4:20
1.24
2.04
1.04
0.94
1 .30
1 .  l 0
1 . 1 6
t . t 7
I  A 1
t . t 7
l - l +
1 . 1 2
0 .81
0.52
0.40
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Anti-Xa assay
1 :  l 0
2 :  l0
3 : 1 0
4 : 1 0
0.85
r . 1  8
t . 28
1.26
0.85
1 .28
1 .35
t .20
2.7 5
6.07
3 .01
2.69
L l 6
1.04
1 .01
t .43
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the reagents used. As with heparin DxN10
the relative activity is quite similar in the
APTT with actin (fig. a) and smaller than
1.00 in the APTT with kaolin cephalin.
Discussion
For the measurement of heparin concen-
trations, it is a condition sine qua non that
the ratio ofthe activities ofthe heparin prep-
arations being compared is independent of
the dilution used;condition of similarity [6].
For the standardisation of heparin prepara-
tions, the relative activities should also be
independent of the assay used [6]. As both
requirements eemed to be met by the com-
mercial nonfragmented heparin, the concen-
trations of these preparations can be deter-
mined and expressed in U/1.
The LMW heparins reveal contradictory
properties in the 5 tested methods. There-
fore, the concentrations of these preparations
cannot unambiguously be expressed in U/1.
Moreover, the relative anti-thrombin activ-
ity of Org. 10172 is also dependent on the
dilution used and cannot even be deter-
mined. In the five assays the response curves
of the APTT with actin (fig. 3) are most sim-
ilar and one can hypothesize that units ofthe
heparin preparations as indicated by the
manufacturer had been determined in an as-
say similar to the APTT with actin. It is,
however, highly questionable if this assay or
any other will reflect the antithrombotic ef-
fect in vivo. It would be in no way justihed to
conclude that two different heparinJike sub-
stances with the same activity in some test
system, will have a similar clinical effect.
Therefore, the therapeutic range will have to
be determined for each preparation.
To determine the therapeutic range one
should be able to monitor the therapy. It
appears quite feasible to construct for each
heparin preparation a curye steep enough to
give reliable readings in a desired range. It is
obvious that clinicians can be provided with
data on the amount of heparin in the pa-
tients' plasma only relative to the activity of
the heparin preparation used for the refer-
ence curve. This makes it possible for clini-
cians to study the relation between a given
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dose and the achieved plasma concentration
as well as the relation between the plasma
concentration and clinical effect.
A related pharmacokinetic problem is still
whether each of the components of a heparin
preparation will behave similarly after injec-
tion. If there is a difference in clearance
between heparin fraction of various molecu-
lar weights, the heparin preparation used for
establishing the reference curves might well
diller from the heparin encountered in the
plasma samples drawn.
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